Recommended Phase 2 Dose for Abemaciclib in Combination With Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results From Study JPCS Part B

Background Cyclin‐dependent kinase 4/6 (CDK4/6) pathway aberrations, including CDK4 or CCND1 amplification, CDKN2A/B loss, retinoblastoma (RB) dysregulation, and cyclin D overexpression, are relevant for pediatric cancers. Abemaciclib, a selective CDK4/6 inhibitor with preferential CDK4 activity and central nervous system (CNS) penetration, induces sustained G1 arrest. Preclinical pediatric models show additive or synergistic activity with temozolomide, supporting further evaluation. Here, the recommended Phase 2 dose (RP2D) for abemaciclib with temozolomide is defined in children and young adults with relapsed/refractory solid tumors. Procedure JPCS Part B was an open‐label, multicenter Phase 1b study using a 3 + 3 design to evaluate continuous abemaciclib (70–115 mg/m 2 orally BID) with temozolomide (100–150 mg/m 2 orally days 1–5) in 21‐day cycles. The primary objective was RP2D determination based on dose‐limiting toxicities (DLTs) and pharmacokinetics. Secondary objectives included safety and antitumor activity. Results Twenty‐six patients (median age 11 years; range, 1–18) with heavily pretreated relapsed/refractory tumors were enrolled. The RP2D was established as 115 mg/m 2 abemaciclib BID on Days 1–21, with 150 mg/m 2 temozolomide on Days 1–5 of 21‐day cycles, based on two DLTs (thrombocytopenia), one at the RP2D. The maximum tolerated dose was not reached. Toxicities reflected expected myelosuppression and predominantly low‐grade gastrointestinal events. Together, 35% and 19% of patients experienced Grades 3 and 4 treatment‐related toxicities, respectively. Steady‐state abemaciclib concentrations aligned with adult efficacy‐associated ranges, with no drug‐drug interactions. Three patients (12%) achieved partial responses and 10 (38%) stable disease, yielding 50% disease control. Three patients had sustained disease control with >6 months on treatment. Conclusions Abemaciclib plus temozolomide is feasible and well‐tolerated and shows preliminary antitumor activity, supporting further evaluation in Phase 2 trials. Trial Registration NCT04238819.

Authors

Institutions

Publication Details

Journal
Pediatric Blood & Cancer
Published
2026-11-18
DOI
https://doi.org/10.1002/1545-5017.70817
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Recommended Phase 2 Dose for Abemaciclib in Combination With Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results From Study JPCS Part B

Holly M. Knoderer, Yanhong Zhou, Álvaro Lassaletta, Antonio Ruggiero et al.
3 links
Pediatric Blood & Cancer
Advanced Breast Cancer Therapies
article

Recommended Phase 2 Dose for Abemaciclib in Combination With Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results From Study JPCS Part B

Holly M. Knoderer, Yanhong Zhou, Álvaro Lassaletta, Antonio Ruggiero, Anne Thorwarth, Amanda K. Sykes, Ayumu Arakawa, Antonio Juan Ribelles, Lindsey Marie Hoffman, Lucas Moreno, Sarah Nabinger
article en

Abstract

Background Cyclin‐dependent kinase 4/6 (CDK4/6) pathway aberrations, including CDK4 or CCND1 amplification, CDKN2A/B loss, retinoblastoma (RB) dysregulation, and cyclin D overexpression, are relevant for pediatric cancers. Abemaciclib, a selective CDK4/6 inhibitor with preferential CDK4 activity and central nervous system (CNS) penetration, induces sustained G1 arrest. Preclinical pediatric models show additive or synergistic activity with temozolomide, supporting further evaluation. Here, the recommended Phase 2 dose (RP2D) for abemaciclib with temozolomide is defined in children and young adults with relapsed/refractory solid tumors. Procedure JPCS Part B was an open‐label, multicenter Phase 1b study using a 3 + 3 design to evaluate continuous abemaciclib (70–115 mg/m 2 orally BID) with temozolomide (100–150 mg/m 2 orally days 1–5) in 21‐day cycles. The primary objective was RP2D determination based on dose‐limiting toxicities (DLTs) and pharmacokinetics. Secondary objectives included safety and antitumor activity. Results Twenty‐six patients (median age 11 years; range, 1–18) with heavily pretreated relapsed/refractory tumors were enrolled. The RP2D was established as 115 mg/m 2 abemaciclib BID on Days 1–21, with 150 mg/m 2 temozolomide on Days 1–5 of 21‐day cycles, based on two DLTs (thrombocytopenia), one at the RP2D. The maximum tolerated dose was not reached. Toxicities reflected expected myelosuppression and predominantly low‐grade gastrointestinal events. Together, 35% and 19% of patients experienced Grades 3 and 4 treatment‐related toxicities, respectively. Steady‐state abemaciclib concentrations aligned with adult efficacy‐associated ranges, with no drug‐drug interactions. Three patients (12%) achieved partial responses and 10 (38%) stable disease, yielding 50% disease control. Three patients had sustained disease control with >6 months on treatment. Conclusions Abemaciclib plus temozolomide is feasible and well‐tolerated and shows preliminary antitumor activity, supporting further evaluation in Phase 2 trials. Trial Registration NCT04238819.

Pediatric Blood & Cancer
Università Cattolica del Sacro Cuore (IT), Eli Lilly (United States) (US), Agostino Gemelli University Polyclinic (IT), Hospital Universitari i Politècnic La Fe (ES), Vall d'Hebron Institut de Recerca (ES), Hospital Infantil Universitario Niño Jesús (ES), Phoenix Children's Hospital (US), Vall d'Hebron Hospital Universitari (ES), Praxis für Hämatologie und Onkologie (DE), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Institut d'Investigació Sanitària Acreditat Institut de Recerca - Hospital Universitari Vall d'Hebron (ES), National Cancer Center Hospital (JP), Charité - Universitätsmedizin Berlin (DE)
Eli Lilly and Company
Good health and well-being
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon